Zuellig Pharma Asia Pacific You started the Chinese operations and have been working in the country for many years but recently moved up to running all operations in Asia Pacific. Are you still closely involved with what’s happening in China? I started the operations in China almost 16 years ago, and I started them…
Shire Deutschland The acquisition of Jerini has to be one of the biggest milestones for Shire Deutschland in its recent history. How have the synergies developed between the two companies, and how is the integration progressing? To quote Dr Werner Föller, head of Shire Deutschland’s Human Genetic Therapies Business Unit, “The integration…
Ipsen France As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the group today? The pharmaceutical industry has been present in France for many years and is one of the country’s traditional…
AstraZeneca France You’ve been at the head of AstraZeneca France for 7 years through during which time there has been a lot of M&A activity in the industry as well as a rising generics market in France and increased regulations for market authorization. How has the business changed for AstraZeneca in this…
GSK France France yet today you work for a foreign multinational within France. Can you speak to the differences in culture and what the transition has been like? I have spent half of my career abroad but always having worked for a French pharmaceutical company whether it was Fournier or sanofi-aventis. Of…
LEEM - Les Enterprises du Medicament What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies which seek to develop, manufacture and market drugs. Leem represents all components of the profession: international groups, medium-sized companies, an important fabric of small,…
FPS - Facophar Santé FPS is a hundred year old organization with roots in the beginning of the last century representing today SME suppliers to the health industries. Given the variety of its membership what are the current priorities of FPS and how does the organization stay relevant to its multiple industries? Firstly I…
LEEM - Les Enterprises du Medicament Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up? I think France has kept up with the world market albeit with some notable differences, namely in terms of our…
France What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that we can no longer live during this crisis without letting people express themselves genuinely. And I don’t mean expression of…
Biomax Informatics Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company and how successful have you been so far in achieving your aims? When I founded the company 10 years ago,…
GlaxoSmithKline Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these evolved since you stepped into that role in April 2010? The ABPI represents the R&D and innovation-based pharmaceutical companies in…
IMS Health Germany Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been the partner of the pharmaceutical industry for over fifty years and has evolved alongside it. IMS today is the partner…
See our Cookie Privacy Policy Here
